Fathom Research · VINATIORGA · Consolidated · as of 9 Sep 2026
It makes about 65% of the world's supply of two obscure molecules, one that goes into ibuprofen and one that helps pull oil out of the ground. Owning most of a small market turns out to be a ceiling as well as a moat, and the share price has spent five years discovering that.
Vinati Organics makes speciality chemicals at four plants in Maharashtra. Its two main products are IBB, an intermediate used to manufacture ibuprofen, and ATBS, a monomer used in enhanced oil recovery and water treatment. It holds roughly 65% of world supply in both. It has since added antioxidants and speciality intermediates.
Sector
Commodities · Specialty Chemicals
Founded
1989
Head office
Mumbai
Revenue (FY26)
₹2,227 cr
Market cap
₹13,859 cr
Promoter holding
74.29%
Fathom view
Position
About 65% of world supply, twice over
Balance sheet
Zero borrowings
Margins
40% operating in FY20, 29% now
Growth
2% a year over three years
Returns
20% on capital, 15% on equity
Working capital
97 days to 130
Promoter
74.3%, unmoved
Valuation
About 31 times, down from roughly 73
Key questionDominating a niche was supposed to be the whole point. Instead the margin has fallen eleven points and revenue has grown 2% a year. Was the old 40% margin the anomaly, or is 29% the floor of something that still compounds?
A specialist chemist that found two molecules too small and too fiddly for the majors to bother with, and then discovered how small those markets are.
IBB and ATBS are difficult, low-volume molecules with demanding customers. A pharmaceutical company buying an ibuprofen intermediate needs consistent purity and audited manufacture, and it will not requalify a supplier casually. An oilfield services firm buying ATBS needs the polymer to behave the same way in every well. Neither market is large enough to attract a global chemical major, and both are hard enough to keep out casual entrants. Vinati found that gap and filled it.
Why has no one else already won? Vinati has won, and that is the difficulty rather than the achievement. With most of world supply in both main products there is very little share left to take, and the markets themselves grow slowly: ibuprofen demand tracks global painkiller consumption, and ATBS demand tracks oilfield activity and water treatment. So the company reached the top of a small hill. What it does next has to come from new molecules, which is exactly what the antioxidants and speciality intermediates businesses are, and they are early.
The economic engine
IBB
Into ibuprofen
About 65% of world supply
ATBS
Into oil recovery and water treatment
About 65% of world supply
Antioxidants
The new leg
About ₹220 crore of FY25 revenue at roughly 40% utilisation
Customers
Global chemical and pharma buyers
Requalification is slow, which is the protection
The limit
How big the niches are
Not how much of them Vinati holds
Where the edge is (and isn’t)
A toll booth on two narrow roads
Toll booth or restaurant
Roughly 65% of world supply in molecules that customers requalify slowly is a genuine toll position. The traffic on both roads is modest and grows with painkiller consumption and oilfield activity.
Was strong, now unclear
Pricing power
A 40% operating margin in FY20 showed how attractive the economics could be. Eleven points of that has gone while the market share did not move, and the accounts alone do not tell you why.
Reached, and it is small
The ceiling
Growth has to come from new products rather than from more share, and revenue has compounded at 2.5% over three years.
Clean
Capital allocation
Zero borrowings, no dilution, share capital unchanged at ₹10 crore, and about a fifth of profit paid out. Capital spending has gone into antioxidants and speciality intermediates rather than into more of the same.
Falling
The referee, return on capital
Return on capital employed was 27% in FY22 and 20% now. Return on equity is 15%. The capital going into new products is in the denominator and not yet in the numerator.
Strategic position
Global chemical majors
BASF, Lanxess and others. Larger, and not interested in molecules this small
↓
Vinati Organics
About 65% of world supply in two niches, debt free, moving into antioxidants
↓
Chinese and regional producers
Compete on price at the commodity end, held back on the audited pharma grades
Why now
The business grew while the valuation collapsed. Over five years the share price compounded at minus 7% a year and profit at 11%, so the multiple contraction explains the entire decline and more. So the question is no longer whether the price got ahead of the business, because it plainly did and has since corrected. The question is what the business does next, and the answer for three years has been very little: revenue up 2.5% a year, profit up 2%, margin down. Management guides 15% volume growth and a 26% to 27% EBITDA margin for FY27, which would be a change of pace.
What has to go right
That the 40% margin era was a moment rather than a normal
That the antioxidant capacity fills without the consolidated margin falling further
That new molecules take years to matter, and the market will not pay for them until they do
Why the business works
Roughly 65% of global supply in both IBB and ATBS
Zero borrowings at March 2026
Five-year operating cash flow at about 103% of reported profit
The antioxidants plant is built and paid for, and running at roughly 40% utilisation
Promoter holding at 74.29%, unchanged, with no dilution
Why the thesis could fail
The EBITDA margin slips below the 26% to 27% management has guided to
Antioxidant utilisation stays near 40% and the plant keeps carrying cost without earnings
FY27 volume growth arrives without profit growth, meaning the extra tonnes earn less
Return on capital employed keeps falling from the 20% it has reached
Oilfield activity softens, which takes ATBS volumes with it
Sector mental models
Customer switching cost
High
Requalifying a pharma intermediate is slow and expensive
Market size
Small
The constraint that the market share figure hides
Input exposure
Moderate
Petrochemical feedstocks, priced outside the company
End-market cyclicality
Mixed
Pharma steady, oilfield activity is not
One sentence to remember
Owning most of a small market protects you and caps you, and the second half arrives later.
01Company Overview
Two molecules explain most of this company. IBB is an intermediate that goes into ibuprofen, so a meaningful share of the world's painkillers begins in Maharashtra. ATBS is a monomer used to thicken the fluid pumped into oil wells to force out more crude, and in water treatment. Vinati makes roughly 65% of global supply of each.
That is an unusual position for an Indian mid-cap and it produced unusual numbers. In FY20 the operating margin was 40% and return on capital reached 27%. Borrowings have been effectively zero throughout, the promoter holds 74.29% and has not moved, and there has been no dilution: share capital has been ₹10 crore for years.
Since then something changed and it is the reason to look at this now. The operating margin fell from 40% to 29%. Revenue went from ₹2,066 crore in FY23 to ₹2,227 crore in FY26, about 2.5% a year, and profit from ₹419 crore to ₹444 crore, about 2%. The share price fell 23% in the last year and has compounded at minus 7% over five, so the multiple has come down from roughly 73 times to 31. The company still dominates its markets. It just stopped growing.
02Business Model & Industry
Unit of revenue: A tonne of a specific molecule. Vinati is paid per tonne of IBB, ATBS, antioxidant or intermediate, at prices negotiated with a small number of large industrial buyers.
Model: Business-to-business manufacture and sale of speciality chemicals, largely exported, sold on contracts and repeat orders rather than spot. No recurring revenue, but customers requalify slowly, so volumes are sticky.
ATBS and speciality monomers50%
The core. Enhanced oil recovery, water treatment, personal care
IBB and aromatics30%
The ibuprofen intermediate and related aromatics. Steady pharma-linked demand
Antioxidants10%
About ₹220 crore in FY25 at roughly 40% utilisation. The new leg
Butyl phenols and other intermediates10%
Downstream speciality intermediates, including the Veeral Organics business
Structure
Niche monopolies inside a large industry. Global chemical majors dominate volume products; small specialists hold molecules too small for them.
Competitors
Regional and Chinese producers at the commodity end. In the audited pharma-grade products, very few.
Pricing power
Some, and the accounts do not show how much. Holding 65% of a market while the margin falls eleven points means share and pricing power are not the same thing here.
Demand driver
Global ibuprofen consumption for IBB, and oilfield activity plus water treatment for ATBS. Antioxidants track polymer and rubber demand. (Structural and slow for pharma, cyclical for oilfield. Neither grows fast.)
TAM
Small. The binding constraint is the size of the market rather than the share of it.
Penetration
Effectively complete in the core products. Antioxidants is early, at roughly 40% utilisation.
Value-chain seat
Upstream intermediate supplier. It sells into other manufacturers' processes, which gives it stickiness and no contact with an end customer.
The business quality is real and the returns have been drifting down for four years, and both matter. Zero debt, cash conversion at about 103% of profit over five years, a promoter who has neither sold nor diluted, and a dominant share of two molecules customers cannot switch away from quickly. Against that: return on capital employed has gone from 27% in FY22 to 20%, the operating margin from 40% in FY20 to 29%, and revenue has barely grown over three years. Part of the return fall is deliberate, because capital has gone into antioxidants and speciality intermediates that are not yet earning. Part of it is the core products earning less per tonne than they did, and the accounts do not separate the two. That distinction is the whole investment question and it is not answerable from the filings alone.
03Valuation Snapshot
Price
₹1,334
Market cap
₹13,859 cr
52W high / low
₹1,850 / ₹1,203
Down about 23% over the year
Stock P/E
30.9
Computed price/EPS = 30.8
EPS (TTM)
₹43.26
Book value
₹305
P/B
4.4
Dividend yield
0.64%
About a fifth of profit paid out
ROCE
19.8%
Was 27% in FY22
ROE
14.9%
04Financial Performance (5Y, in Crores)
FY22
₹1,616net ₹347 · 21.5%
FY23
₹2,066net ₹419 · 20.3%
FY24
₹1,900net ₹323 · 17%
FY25
₹2,248net ₹405 · 18%
FY26
₹2,227net ₹444 · 19.9%
RevenueNet profit₹ crore · % = PAT margin
05Key Ratios
ROE
14.9%
Five-year average 17%
ROCE
19.8%
27% in FY22, 28% in FY23
Debt / equity
0.00
Zero borrowings at March 2026
Operating margin
29%
Was 40% in FY20 and 25% in FY24
Debtor days
85
Ranged 72 to 106 over seven years
Working capital days
130
Was 97 in FY20
06Cash Flow Forensics (in Crores)
FY22
OCF₹127Capex₹174FCF₹-47
FY23
OCF₹515Capex₹315FCF₹200
FY24
OCF₹332Capex₹397FCF₹-65
FY25
OCF₹458Capex₹497FCF₹-39
FY26
OCF₹558Capex₹270FCF₹288
Operating cash flow over five years comes to about 103% of reported profit, so the earnings are cash. What the free cash flow column shows is a company that has been spending: negative in FY22, FY24 and FY25, positive in FY23 and FY26. That is capital going into the antioxidants plant and the speciality intermediates, funded entirely from operations with borrowings at zero. Nothing here needs explaining away. The line to keep an eye on is working capital days, which have gone from 97 in FY20 to 130, with debtor days at 85. Not yet a problem, and it has moved one way for six years.
07Growth
Sales CAGR 5Y
18%
Measured from FY21, a covid year with revenue of ₹954 crore
Sales CAGR 3Y
3%
Sales growth TTM
5%
Profit CAGR 5Y
11%
Profit CAGR 3Y
2%
Profit growth TTM
5%
FY27 guidance
15% volume growth
With a 26% to 27% EBITDA margin
08Management
The promoter group holds 74.29% and has not moved a basis point across six reported quarters. Share capital has been ₹10 crore throughout, so nobody has been diluted, and borrowings ended FY26 at zero. About a fifth of profit is paid out. On every conventional test of promoter behaviour this is clean.
Judge them instead on where the money went. Capital spending ran at ₹315 crore, ₹397 crore and ₹497 crore across FY23 to FY25, which took free cash flow negative in two of those years, and it was funded entirely from operations. That money went into antioxidants, where Veeral Additives was merged in during FY24 to bring the value chain in-house, and into speciality intermediates through Veeral Organics. The antioxidants business generated about ₹220 crore of revenue in FY25 at roughly 40% utilisation, so most of the capacity is built and idle.
That is a defensible use of a strong balance sheet by a company that had run out of room in its core products, and it also explains part of the return fall: the capital is in the denominator and the earnings are not yet in the numerator. Management guides 15% volume growth and a 26% to 27% EBITDA margin for FY27, with ₹200 crore to ₹250 crore of further capital spending and Veeral Organics revenue expected from the third quarter. Those are dated claims that can be checked.
Narrow, and it protects two products rather than a company
Roughly 65% of world supply in both IBB and ATBS, built over decades
Requalification cost: a pharma customer will not casually change the source of an ibuprofen intermediate
Process knowledge in molecules too small to attract a global chemical major
Backward integration into the antioxidant value chain through the Veeral Additives merger
The moat is real and unusually narrow: it protects two molecules, not a company. Customers requalify slowly and the markets are too small for a BASF to bother with, which is why Vinati could hold 65% of world supply and earn a 40% operating margin. Then watch what happened to that margin. It is 29% now, and the market share did not change. So the moat kept competitors out of the products and did not keep the economics intact, which is a distinction worth sitting with. A dominant share tells you who supplies the market. It does not tell you what supplying it is worth.
11The Story So Far
FY20 was the high-water mark. Revenue of ₹1,029 crore, an operating margin of 40%, profit of ₹334 crore, and a return on capital that would reach 27% two years later. The market treated it accordingly, and on the price history the shares changed hands at something close to 73 times earnings around FY21.
What followed was not a collapse. Revenue roughly doubled to ₹2,066 crore by FY23 as volumes grew, and profit reached ₹419 crore. But the margin fell every step of the way: 40%, 37%, 27%, 28%. FY24 was the difficult year, with revenue falling to ₹1,900 crore and profit to ₹323 crore. FY25 and FY26 recovered to ₹2,248 crore and ₹2,227 crore of revenue and ₹405 crore and ₹444 crore of profit.
So across three years revenue has grown 2.5% a year and profit 2%. Over the same period the share price fell, compounding at minus 12% over three years and minus 23% in the last twelve months. The company spent those years building antioxidant and intermediate capacity that is still largely idle.
12Risks
The margin. It has gone from 40% in FY20 to 29%, and the market share did not change over that period. The accounts do not separate how much is mix as antioxidants ramp and how much is pricing in the core molecules, and that distinction decides the investment. High.
A market too small to grow into. At roughly 65% of world supply in both main products, growth has to come from new molecules rather than more share. Revenue has compounded at 2.5% over three years, which is what that constraint looks like. High.
The new products may stay small. Antioxidants was about ₹220 crore of FY25 revenue at roughly 40% utilisation. The capacity is built and paid for, and until it fills, the return on capital carries the cost without the earnings. Medium-High.
Oilfield exposure. ATBS demand tracks enhanced oil recovery activity, which moves with the crude price and with drilling budgets Vinati does not influence. Medium.
Working capital drift. Days have gone from 97 in FY20 to 130. Not yet a problem, and the direction has been consistent for six years. Medium.
Chinese competition at the commodity end. The audited pharma grades are protected by requalification; the less demanding grades are not. Medium.
13What the Headline Numbers Hide
✓ clean! caution✕ red flag– n/a
✓
Profit up while operating cash flow lags
Five-year operating cash flow at about 103% of reported profit. ₹558 crore in FY26 against ₹444 crore of profit.
!
Growth measured from a distorted base
The 18% five-year sales figure starts in FY21, when revenue was ₹954 crore in a covid year. The three-year figures of 3% and 2% are the ones to use.
✕
Margin falling
Operating margin from 40% in FY20 to 29%. This is the central question of the report, and it is a fall rather than the usual unexplained jump.
✓
Promoter selling or dilution
Holding at 74.29%, unchanged across six quarters. Share capital ₹10 crore throughout.
✓
Debt disguising the returns
Zero borrowings at March 2026, so the 20% return on capital is unlevered.
✓
Other income propping up profit
₹9 crore against ₹109 crore of quarterly profit. Not a factor.
!
Working capital deteriorating
97 days in FY20 to 130 in FY26, with debtor days at 85. A slow drift in one direction.
Sector checklist
✓
Market position
Roughly 65% of world supply in both IBB and ATBS.
✓
Customer switching cost
Requalifying a pharma intermediate is slow and expensive, which is what keeps the volumes.
!
Capacity utilisation
Antioxidants at roughly 40% in FY25. Capacity built and largely idle.
!
New product development
Antioxidants and speciality intermediates are the answer to the growth question, and both are early.
!
Input cost pass-through
Petrochemical feedstocks are priced outside the company, and the margin fall suggests pass-through has been imperfect.
!
End-market concentration
Two molecules into pharma and oilfield. Narrow, and the oilfield half is cyclical.
14Two-Engine Assessment
Engine one: stalled, and spending
Over three years revenue has compounded at 2.5% and profit at 2%, on a business that dominates both its main products. That combination is the report. The cash is real, at about 103% of profit over five years, and the balance sheet carries no debt, so this is not a quality problem. It is a growth problem with two possible causes. Either the core molecules are earning less per tonne than they used to, in which case the 40% margin era was the anomaly. Or the margin is diluted by antioxidants and intermediates ramping at low utilisation, in which case it recovers as the capacity fills. Management's FY27 guidance implies the second, and the quarterly margin has already moved between 24% and 30% across the last eight quarters.
Engine two: has already done its work
The multiple has fallen from roughly 73 times around FY21 to 31 now, while profit compounded at 11% over the same five years. That is a compression of about 16% a year, and it is the largest single thing that has happened to this share. So a buyer today is not paying the price that the FY20 margin and the 65% market share once justified. Whether 31 times is now reasonable depends entirely on which explanation of the margin fall is right, because 31 times a business growing 2% is expensive and 31 times a business about to grow 15% in volume is not.
The market share was never the question, and treating it as the answer is how this share got to 73 times in the first place. Owning most of two small markets is a genuinely strong position and it caps you as firmly as it protects you, which is why revenue grows at 2.5%. What is undecided is the margin, and the fair reading is that nobody can settle it from the filings: the antioxidants dilution and a weaker core would look identical in the consolidated numbers. Two things would separate them within four quarters. If utilisation rises from 40% while the EBITDA margin holds at 26% to 27% and return on capital turns up from 20%, the dilution explanation was right. If volumes grow and the margin keeps sliding, the core is the problem and the multiple has further to fall. Watch all three, because filling the plant at poor incremental returns would look like progress and would not be.
15Mental-Model Lenses
Sixty-five percent of a small thing
Vinati makes about 65% of the world's IBB and about 65% of its ATBS. Read that as a description of the ceiling rather than as a promise. There is very little share left to take in either product, so growth has to come from the markets themselves getting bigger, and they grow with global ibuprofen consumption and with oilfield activity. Neither is fast. That is why a company with a genuinely dominant position has produced 2.5% revenue growth over three years, and it is not a failure of execution. It is what happens when you finish winning. The useful version of the market-share figure is not how much of the market you hold; it is how much of the market there is.
Eleven points of margin, and the share stayed the same
The operating margin was 40% in FY20 and is 29% now. Across those six years the market share did not move. That is the most interesting fact in this report, because it separates two things people usually run together: dominating a market and earning well from it. Something changed in the economics while nothing changed in the position. The candidates are ordinary rather than dramatic. Antioxidants and intermediates now sit in the same consolidated margin and are ramping at roughly 40% utilisation, which dilutes. Or the core molecules simply fetch less than they did. Both would look identical in the figures published, and the difference between them is the difference between a temporary dip and a permanently smaller company.
The capital is already spent
Capital spending ran at ₹315 crore, ₹397 crore and ₹497 crore across FY23 to FY25, which took free cash flow negative in two of those three years, funded entirely from operations with no borrowing. That money is in antioxidants, where Veeral Additives was merged in during FY24, and in speciality intermediates. The antioxidants business did about ₹220 crore of revenue in FY25 at roughly 40% utilisation. So the plant exists, it is paid for, and it is running at less than half. That is why return on capital employed has gone from 27% to 20% without anything going wrong: the assets are in the denominator and the earnings are not yet in the numerator. Filling that capacity is the single most checkable thing about this company over the next two years.
The de-rating has already happened
Five years ago these shares changed hands at something close to 73 times earnings. Today the figure is 31. Over the same five years profit compounded at 11%, so the business grew while the price fell, and the multiple absorbed the entire difference at about 16% a year. Most reports about a company like this are written on the way down; this one is being written afterwards. That changes what you are deciding. You are not asking whether the market was too optimistic about a niche chemical maker, because it plainly was and has stopped being. You are asking what 31 times is worth for a business whose growth is 2% and whose guidance says 15% volume, and that question turns on the margin rather than on sentiment.
17Summary
Vinati Organics dominates world supply of IBB and ATBS, has no debt, converts profit to cash, and has a promoter who has neither sold nor diluted. On the usual measures this is a high-quality company, and it has produced 2.5% revenue growth and 2% profit growth over three years while its operating margin fell from 40% to 29% and its return on capital from 27% to 20%. Part of that fall is the capital deliberately put into antioxidants and speciality intermediates, which are built, roughly 40% utilised, and not yet earning. Part of it is the core molecules earning less per tonne, and the filings do not separate the two. The share price has already reflected a great deal of this: it has fallen for five years, and the multiple has more than halved. Management has guided to a step up in volumes and a margin floor for FY27, with Veeral Organics revenue expected from the third quarter. The test is all three together: utilisation rising from 40%, the EBITDA margin holding at 26% to 27%, and return on capital turning back up from 20%. Volume alone would not settle it, because the plant could fill at returns that make the problem worse.